<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01502384</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-11-NG-0463</org_study_id>
    <nct_id>NCT01502384</nct_id>
  </id_info>
  <brief_title>A Longitudinal Study in 1st Degree Relatives of Parkinson's Disease (PD) Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a longitudinal study in healthy 1st degree relatives of patients with Parkinson's
      Disease (PD) carriers of a genetic mutation in genes that are known to increase the risk for
      PD. The purpose of this study is to explore the association between genetic mutations in the
      known genes and early preclinical symptoms such as motor, sensory, autonomic, behavioral and
      cognitive functions.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>healthy relatives</arm_group_label>
    <description>healthy 1st degree relatives of PD patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neurological examination</intervention_name>
    <description>motor and cognitive functions</description>
    <arm_group_label>healthy relatives</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy 1ST degree realtives of PD patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy 1ST degree relatives of PD patients with known genotype that participated in
             an earlier genetic study at the sourasky medical center.

        Exclusion Criteria:

          -  subjects with cognitive decline by the parameters defined in DSM- IV

          -  subjects with psychiatric disorder

          -  subjects unable to sign a consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anat Mirelman, PhD</last_name>
    <phone>972-3-6974958</phone>
    <email>anatmi@tasmc.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anat Mirelman, PhD</last_name>
      <phone>972-3-6974958</phone>
      <email>anatmi@tasmc.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Nir Giladi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Di Monte DA. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2003 Sep;2(9):531-8. Review.</citation>
    <PMID>12941575</PMID>
  </reference>
  <reference>
    <citation>Di Monte DA, Lavasani M, Manning-Bog AB. Environmental factors in Parkinson's disease. Neurotoxicology. 2002 Oct;23(4-5):487-502. Review.</citation>
    <PMID>12428721</PMID>
  </reference>
  <reference>
    <citation>Huang Y, Cheung L, Rowe D, Halliday G. Genetic contributions to Parkinson's disease. Brain Res Brain Res Rev. 2004 Aug;46(1):44-70. Review.</citation>
    <PMID>15297154</PMID>
  </reference>
  <reference>
    <citation>Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 2004 Sep;27(9):561-8. Review.</citation>
    <PMID>15331239</PMID>
  </reference>
  <reference>
    <citation>Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med. 2004 Jul;10 Suppl:S58-62. Review.</citation>
    <PMID>15272270</PMID>
  </reference>
  <reference>
    <citation>von Bohlen und Halbach O, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol. 2004 Jun;73(3):151-77. Review.</citation>
    <PMID>15236834</PMID>
  </reference>
  <reference>
    <citation>Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, Strain KJ, Maraganore DM. LRRK2 mutations in Parkinson disease. Neurology. 2005 Sep 13;65(5):738-40.</citation>
    <PMID>16157908</PMID>
  </reference>
  <reference>
    <citation>Wilk JB, Lash TL. Risk factor studies of age-at-onset in a sample ascertained for Parkinson disease affected sibling pairs: a cautionary tale. Emerg Themes Epidemiol. 2007 Apr 4;4:1.</citation>
    <PMID>17408493</PMID>
  </reference>
  <reference>
    <citation>Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology. 2007 Oct 16;69(16):1595-602.</citation>
    <PMID>17938369</PMID>
  </reference>
  <reference>
    <citation>Clark LN, Nicolai A, Afridi S, Harris J, Mejia-Santana H, Strug L, Cote LJ, Louis ED, Andrews H, Waters C, Ford B, Frucht S, Fahn S, Mayeux R, Ottman R, Marder K. Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov Disord. 2005 Jan;20(1):100-3.</citation>
    <PMID>15517591</PMID>
  </reference>
  <reference>
    <citation>Thaler A, Ash E, Gan-Or Z, Orr-Urtreger A, Giladi N. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. J Neural Transm (Vienna). 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. Review.</citation>
    <PMID>19756366</PMID>
  </reference>
  <reference>
    <citation>Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol. 2011 Jan;69(1):193-7. doi: 10.1002/ana.22165.</citation>
    <PMID>21280089</PMID>
  </reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2011</study_first_submitted>
  <study_first_submitted_qc>December 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2011</study_first_posted>
  <last_update_submitted>December 29, 2011</last_update_submitted>
  <last_update_submitted_qc>December 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy 1st degree relatives of pd patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

